|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Servizio di Immunoematologia e Trasfusione,
Centro Emofilia, and Servizio di Microbiologia, Azienda Ospedaliera di
Verona, Verona, Italy; Servizio di Immunoematologia e Trasfusione,
Centro Emofilia, Ospedale S. Chiara, Trento, Italy;
5a Divisione Medica, Centro Emofilia, Azienda
Ospedaliera di Parma, Parma, Italy; Medicina Interna A, Dipartimento di
Medicina e Sanità Pubblica and Istituto di Chimica e Microscopia
Clinica, Università di Verona, Verona, Italy.
This study looked at 102 anti-hepatitis C virus
(HCV)-positive, hepatitis B virus (HBV)-negative, and HIV-negative
patients (median age, 45.1 years; range, 15-71) affected by hereditary bleeding disorders who have been infected with HCV for 15 to 34 years
(median, 25.1). All these patients were infected before the mid 1980s
because of non-virally inactivated pooled blood products. Fourteen
patients (13.7%) were HCV-RNA negative with no signs of liver disease
and were considered to have cleared the virus. Eighty-eight patients
(86.3%) were HCV-RNA positive. The HCV genotype distribution was 1a in
20.5%, 1b in 36.4%, 2 in 17.0%, 3 in 15.9%, 4 in 3.4%, and mixed
in 6.8% of cases. Twenty-four patients (23.5%) had serum
cryoglobulins, symptomatic in 4 cases, and associated with liver
disease and with genotype 1. Among the 88 HCV-RNA-positive patients,
15 (17.0%) had normal alanine aminotransferase levels and abdominal
ultrasound, 61 (69.3%) had nonprogressive chronic hepatitis, and 12 (13.7%) had severe liver disease (6 [6.9%] liver cirrhosis, 4 [4.5%] hepatic decompensation, and 2 [2.3%] hepatocellular
carcinoma) after a follow-up period of 25 years. There were 3 (3.4%)
liver-related deaths. HCV genotype 1, patient's age at evaluation,
duration of infection, and severity of congenital bleeding disorder
were associated with more advanced liver disease. The results
confirm the slow progression of HCV infection in HIV-negative hemophiliacs.
(Blood. 2001;98:1836-1841) Hepatitis C virus (HCV) infection is a major
problem for patients affected by hereditary bleeding disorders treated
with factor concentrates during the 1970s.1-4 In fact,
because the concentrates were non-virus inactivated and were prepared
from a large pool of plasma, virtually all patients treated with these
products were infected with HCV at the time of the first
infusion.5-8 Because the onset of the infection can be
reasonably estimated (first treatment with non-virus-inactivated blood
products), these patients represent a unique model for studying
the natural history of HCV infection and associated
complications.9-21 The course of hepatitis can be
accurately assessed in these patients because they are seen regularly
at hemophilia centers with laboratory, clinical, and
instrumental tests.
Studies of the natural history of HCV infection in persons with
hemophilia are limited.21-25 Furthermore, most of the few
studies published so far refer to hemophiliacs coinfected with
HIV,26-30 which is a well-known risk factor for a more
rapid progression of liver disease and could be a confounding factor in
evaluating the natural history of HCV infection.
In this retrospective study, we report the natural history of HCV
infection and the progression of chronic HCV-related liver disease in a
cohort of 102 HIV and hepatitis B virus (HBV) seronegative hemophiliacs
followed at 3 hemophilia centers in northern Italy and exposed to the
virus for a period of up to 34 years.
Patients
Study design
Laboratory assays Serum cryoglobulins. The presence of serum cryoglobulins was evaluated as follows. After collecting the blood at 37°C, serum was cleared by centrifugation at 2000g for 15 minutes, stored in a cryocrit tube at 4°C for 7 days, and examined daily. The formation of the precipitate was confirmed visually. Samples were considered positive for cryocrit values more than 0.5%, after checking the heat resolubility of the cryoprecipitate. Cryoglobulins were identified as immunoglobulin composition by immunoblotting assay and classified as type II when rheumatoid factor was monoclonal or as type III when rheumatoid factor was policlonal.31 Serologic anti-HCV assay. For the detection of immunoglobulin G antibodies to HCV we used an indirect enzyme immunoassay (Cobas Core Anti-HCV EIA; Roche Diagnostic Systems, Branchburg, NJ) containing epitopes from the core and the NS3, NS4, and NS5 proteins to improve the clinical sensitivity as well as the clinical specificity of anti-HCV antibody detection. Specimens with absorbance values more than 1.1 times the cutoff value were retested in duplicates, and, if the values were again more than 1.1 times the cutoff value, the specimens were considered reactive for HCV antibodies. In this case the specimens were confirmed by more specific methods as immunoblot assay (Inno-Lipa HCV II; Innogenetics, Zwijndrecht, Belgium). HCV RNA qualitative testing and HCV genotyping.
HCV RNA was reverse transcribed and amplified using a commercially
available HCV RNA assay (Cobas Amplicor HCV; Roche Diagnostic Systems),
with primers to the highly conserved 5' noncoding region. Biotin-labeled amplified products were genotyped using a commercially available line probe assay (Inno-Lipa HCV II; Innogenetics). In brief,
the labeled amplicons were reversely hybridized to oligonucleotide probes directed against variations found on the 5' noncoding regions of
the HCV genome.32 The specificity can be obtained with
very stringent hybridization condition (50°C ± Statistical analysis For analysis of normally distributed continuous data, we used Student t test; for analysis of categorical data, we used the chi-square or Fisher exact tests. We used the one-way analysis of variance to compare the categories of patients.
Fourteen of the 102 patients (13.7%) enrolled were HCV-RNA negative, whereas the remaining 88 (86.3%) were HCV-RNA positive. All the patients were infected before 1985 (date of introduction of sterilized concentrates) because of non-virus-inactivated clotting factor concentrates. The median age at infection was 20.1 years (range, 1-56). The average duration of infection was 25.1 years (range, 15-34 years). The 14 patients (13.7%) who have cleared the virus and 15 (17.0%) of the 88 HCV-RNA-positive patients had no laboratory, clinical, or instrumental signs of liver disease during the regular follow-up controls. Seventy-three (83.0%) of the 88 HCV-RNA-positive patients showed liver disease; 61 of them (69.3%) had chronic hepatitis and 12 (13.7%) had liver cirrhosis. The average time lapse between the infection and the onset of liver cirrhosis was 21.6 years (range, 6-32). Among the 12 patients with liver cirrhosis, 4 patients (4.5%) developed hepatic decompensation after an average period of 4.3 years (range, 2-8) from the onset of liver cirrhosis and 27.5 years (range, 23-32) from the HCV infection, respectively. Two patients (2.3%) with liver cirrhosis developed HCC 4 and 8 years, respectively, after the diagnosis of liver cirrhosis (29 and 32 years from the HCV infection). There were 3 (3.4%) liver-related deaths (2 patients with hepatic decompensation and 1 patient with HCC). All the 88 HCV-RNA-positive hemophiliacs were tested for HCV genotype.
The HCV genotype distribution was 1a in 18 patients (20.5%), 1b in 32 patients (36.4%), 2 in 15 patients (17.0%), 3 in 14 patients
(15.9%), 4 in 3 patients (3.4%), and mixed in 6 patients (6.8%;
1a + 1b in 5 cases and 1a + 2 in 1 case). There were no type
5 and 6 infections. Genotype 1 was the most frequent among HCV
genotypes because it was detected in 56 of 88 cases (63.6%; 18 cases
1a, 32 cases 1b, 5 cases 1a + 1b, and 1 case 1a + 2). Table
1 shows epidemiologic, clinical, and
virologic characteristics of the 102 HCV antibody-positive
hemophiliacs. There was no difference in demographic features or
severity of hemophilia between the patients who had spontaneously
recovered and those who developed persistent infection. Table
2 shows the HCV genotypes according to
liver status. Ten of the 56 patients (17.9%) with genotype 1 showed a
progression of HCV infection with liver cirrhosis in 4 cases (7.1%),
hepatic decompensation in 4 cases (7.1%), and HCC in 2 cases (3.6%).
On the contrary, only 2 of the 32 patients (6.2%) with other genotypes
had liver cirrhosis (P < .001). None of them had hepatic
decompensation or HCC. Table 3 correlates
the liver status with epidemiologic and clinical features of the 88 HCV-RNA-positive hemophilic patients. Patients with severe liver
disease were older and had been exposed for longer to HCV virus than
patients with normal serum transaminases or chronic hepatitis
(P = .02 and .03, respectively). Furthermore, the
progression of HCV infection was associated with a more severe congenital bleeding disorder. On the contrary, there was no correlation between the hepatic status and gender.
Twenty-four patients (23.5%) had serum cryoglobulins typed in 16 of 24 cases: type II (mixed cryoglobulinemia) in 14 patients (87.5%) and
type III in 2 patients (12.5%). No HCV-RNA-negative patients had
circulating cryoglobulins. Cryocrit ranged from 1% to 10%. The 1b HCV
genotype that was more frequently present (8 of 24, 33.3%) in
cryoglobulinemic patients, followed by 1a (6 of 24, 25.0%), 2 (5 of
24, 20.8%), 3 (4 of 24, 16.7%), and 1a + 1b (1 of 24, 4.2%).
The difference between HCV genotype 1 and other genotypes was
statistically significant (15 of 24 [62.5%] versus 9 of 24 [37.5%], P < .001). Twenty-three of the 24 cryoglobulinemic patients (95.8%) had liver disease: 18 (75.0%) had
chronic hepatitis, 2 patients (10.0%) had liver cirrhosis, 2 patients
(10.0%) had hepatic decompensation, and 1 patient (5.0%) had HCC.
Four (16.7%) of the 24 patients with serum cryoglobulins developed
cryoglobulinemic syndrome (type II mixed cryoglobulinemia in 3 cases
and type III in 1 case); 2 of them had mild purpura and 2 developed
systemic vasculitic disease associated in one case with
cryoglobulinemic nephropathy. Three of those 4 symptomatic patients had
chronic hepatitis and 1 had liver cirrhosis. HCV genotype was 1b in 2 cases, 2 in 1 case, and 3 in 1 case. The average time lapse between the
HCV infection and the appearance of cryoglobulins was 14.4 years
(range, 7-22). Table 4 compares the
characteristics (sex, age at infection, duration of infection,
genotype, primary disease, and hepatic status) of the patients with and
without serum cryoglobulins. The HCV genotype 1, the age at infection,
the duration of infection, and the severity of the congenital bleeding
disorders were associated with the presence of serum cryoglobulins.
The introduction of lyophilized large donor pool clotting factor concentrates in the early 1970s dramatically changed the hemophilia treatment permitting home therapy for bleeding episodes and a safer management of surgical procedures.1-4 However, until 1985 when virucidal treatment was introduced, the concentrates were not subjected to viral inactivation during preparation, and they were largely responsible for the transmission of HCV infection in hemophiliacs. In fact, because clotting factor concentrates are prepared from plasma pools obtained from thousands of donors, virtually all patients treated with non-virally inactivated concentrates were infected with HCV at the time of the first infusion.5,6 Chronic hepatitis C is an important cause of morbidity and mortality in patients affected by hereditary bleeding disorders treated with factor concentrates during the 1970s, and sometimes it is a more serious problem than the primitive coagulopathy.2,3,7 Because the onset of infection can be reasonably estimated (first treatment with non-virus-inactivated blood products), these patients represent a unique model for studying the natural history of HCV infection and associated complications.22-25 The course of hepatitis can be accurately assessed in these patients because of the long-term follow-up and because they are seen regularly throughout their life at hemophilia centers with laboratory, clinical, and instrumental tests. In this retrospective study we reported a cohort of 102 HCV antibody-positive hemophiliacs treated at 3 hemophilia centers in northern Italy who had been exposed to the virus for 15 to 34 years. To avoid any possible interference with the natural history of HCV infection, we evaluated only patients that were HBV and HIV seronegative with no history of drug addiction or alcohol abuse and untreated for hepatitis C. Fourteen percent of these patients were HCV-RNA negative and none of them had alterations of alanine aminotransferase values during the follow-up period; these patients were considered to have cleared the virus. Among the 88 HCV-RNA-positive patients, 17.0% (15 patients) had no signs of liver disease during the follow-up period, 69.3% (61 patients) had a stable liver disease (nonprogressive chronic hepatitis), and 13.7% (12 patients) developed liver cirrhosis over a period of 21.6 years from infection. Liver failure and HCC occurred in 4.5% (4 patients) and 2.3% (2 patients) of patients after 27.5 and 30.5 years, respectively, from infection. On the whole, among the 102 HCV antibody-positive hemophiliacs evaluated in this study, only 11.8% had a progressive liver disease after an average follow-up period of 25.1 years (Table 1). Thus, our data are similar to those reported in literature9,14-18 for non-hemophilic HCV-infected patients and confirm the slow progression of HCV infection in HIV-seronegative hemophiliacs.24,25 Genotype 1 was the most frequent among HCV genotypes (Table 1). In fact, it was detected, alone, or associated with other genotypes in 63.6% of cases. HCV genotype distribution in our cohort of patients is similar to that observed generally in the Italian population35 and in other studies on hemophiliacs from the same Italian regions,36,37 but it is quite different from data coming from trials on hemophiliacs in other countries.38-44 Furthermore, as hemophiliacs have been exposed to clotting factor concentrates prepared from thousands of donors, some of them have been infected by multiple HCV genotypes. In our study the prevalence of mixed infection is 7% which is similar to that reported in literature.36-44 On analyzing the epidemiologic, clinical, and virologic features of the 88 HCV-RNA-positive patients (Tables 2,3) we observed that a more advanced liver disease was associated with HCV genotype 1, a higher age at evaluation, and a more severe congenital bleeding disorder. As in other studies,23,26 we also identified the duration of infection as an important variable of progression of liver disease: The longer the exposure to HCV, the more severe the liver disease. These last risk factors are strictly correlated. In fact, patients with more severe hemorrhagic disorders had received non-virally inactivated factor concentrates and had been infected at a younger age than patients with mild bleeding disease and thus had a longer-lasting infection. Similarly, the older age at the time of evaluation reflects the longer duration of infection. Furthermore, we must consider the immunosuppressive effect of the clotting factor concentrates that could have favored the HCV progression.45 Patients with severe hemophilia were likely to have been treated more frequently with blood products than patients with mild hemophilia. Previous studies22-24 have found an association between the age at infection and the liver disease progression. Patients infected older than age 40 years had the most aggressive liver disease. We did not find this correlation because of the younger median age at infection (20 years) of our cohort of patients. Among HCV genotypes, type 1 appeared to be associated with the fastest progression of liver disease in our study. In fact, it was detected in 64% of patients with chronic hepatitis and in 75% of patients with severe liver disease. If there are no doubts about the association between the duration of HCV infection and severity of liver disease,16-18,23,26 more uncertainties exist as to the role of HCV genotype 1 on liver disease progression.37-44 Our study also confirms for hemophiliacs the observations in non-hemophilic patients15,18,44 about the greater virulence of genotype 1. HCV infection is now recognized as a major risk factor for the development of HCC.46-49 This complication was first described in patients with congenital bleeding disorders in 1991 by Tradati et al.46 They reported a survey of 11 801 hemophiliacs from 54 centers in the United States and Europe and found 10 cases of HCC, all in patients with cirrhosis, with a prevalence 30 times higher than normally expected. The high prevalence of HCC in hemophiliacs infected with HCV was confirmed by further studies.47-49 A prospective trial47 analyzed the risk of developing HCC in a cohort of 385 Italian hemophiliacs of whom 6 developed HCC during a 2-year follow-up. We found a similar prevalence in our Italian hemophiliacs infected with HCV because 2% of them developed HCC. Our study also confirmed the previous findings48,49 about the presence of liver cirrhosis, the duration of infection, and the genotype 1b as important risk factors for developing HCC. Both patients with HCC had liver cirrhosis and had been infected 30 years previously by HCV genotype 1b. Many studies have shown a strong association between HCV infection and the presence of serum cryoglobulins.50-53 Serum cryoglobulins have been detected in 19% to 55% of patients with chronic HCV infection. Such cryoglobulins may be clinically significant and associated with a systemic vasculitic disorder in 12% to 30% of cases.52,53 Although most of these studies refer to non-hemophiliacs, our results are consistent with them. In our study of 102 HCV antibody-positive hemophiliacs, 24% of the patients developed serum cryoglobulins after an average time of 14 years from infection, with clinical symptoms in 17% of them. This last finding is in contrast with what Santagostino et al36 reported. They found no clinical signs or symptoms of systemic vasculitis in a cohort of 135 hemophiliacs with chronic HCV infection. In accordance with previous studies,36,50-53 we identified a positive correlation between genotype 1, the presence of chronic hepatitis or severe liver disease, the duration of hepatitis C, and the risk of producing serum cryoglobulins. In our study, only the 2 patients with HCC underwent liver biopsy. Whereas liver biopsy is strongly recommended in non-hemophilic HCV-infected patients to assess their liver status, its role in hemophilic patients with HCV liver disease is still controversial.54-58 Even if many groups have reported that liver biopsy could be done safely in hemophiliacs after coagulation factor replacement,55,57-59 fatal bleeding following liver biopsy has been reported.58 Nowadays, the availability of many laboratory (serological, polymerase chain reaction testing, and genotype analysis of HCV) and instrumental (ultrasound and computed tomography) techniques offers the possibility to follow accurately and safely these patients. For this reason we have chosen to manage our HCV-infected hemophiliacs without liver biopsy using clinical history (first time of infusion of nonvirus-inactivated clotting factors and duration of infection), laboratory, and instrumental tests to evaluate their liver status. Studies of the natural history of HCV infection in persons with hemophilia are limited.22-25 Furthermore, most of the few studies published26,27 so far refer to hemophiliacs coinfected with HIV, which is a well-known risk factor for a more rapid progression of liver disease. Thus, in these studies, HIV coinfection could be a confounding factor in evaluating the natural history of HCV infection and could explain the higher incidence of severe liver disease observed. On the contrary, our study shows the slow progression of hepatitis C in HCV-positive and HIV-negative hemophiliacs and confirms that the natural history of HCV infection in these patients is not different from those without congenital bleeding disorders.
Submitted April 9, 2001; accepted May 17, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Massimo Franchini, Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy; e-mail: giorgio.gandini{at}mail.azosp.vr.it.
1. Fried MW. Management of hepatitis C in the hemophilia patient. Am J Med. 1999;107:85-89[Medline] [Order article via Infotrieve]. 2. Makris M, Preston FE, Triger DR, et al. Hepatitis C antibody and chronic liver disease in hemophilia. Lancet. 1990;335:1117-1119[CrossRef][Medline] [Order article via Infotrieve].
3.
Troisi CL, Hollinger FB, Hoots WK, et al.
A multicenter study of viral hepatitis in a United States hemophilic population.
Blood.
1993;81:412-418 4. Lee CA. Hepatitis C infection and its management. Haemophilia. 2000;6:133-137. 5. Morfini M, Mannucci PM, Ciavarella N, et al. Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation. Vox Sang. 1994;67:178-182[Medline] [Order article via Infotrieve].
6.
Brettler DB, Alter HJ, Dienstag JL, Forsberg AD, Levine PH.
Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients.
Blood.
1990;76:254-256 7. Eyster ME. Liver disease in hemophilia. In: Forbes CD,Aledort LM,Madhok R, eds. Hemophilia. London United Kingdom: Chapman and Hall Medical; 1997:259-274. 8. Meijer K, Smid WM, van der Meer J. Treatment of chronic hepatitis C in haemophilia patients. Haemophilia. 2000;6:605-613[CrossRef][Medline] [Order article via Infotrieve]. 9. Alberti A, Chemello L, Benvegnu' L. Natural history of hepatitis C. J Hepatol. 1999;31(suppl 1):17-24. 10. Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. J Hepatol. 1999;31(suppl 1):80-83. 11. Zoulim F. Hepatitis C virus infection in special groups. J Hepatol. 1999;31(suppl 1):130-135. 12. Seef LB. Why is there such difficulty in defining the natural history of hepatitis C? Transfusion. 2000;40:1161-1164[CrossRef][Medline] [Order article via Infotrieve]. 13. Alter HJ, Seef LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35[CrossRef][Medline] [Order article via Infotrieve].
14.
Seef LB, Miller RN, Rabkin CS, et al.
45-year follow-up of hepatitis C virus infection in healthy young adults.
Ann Intern Med.
2000;132:105-111
15.
Liang TJ, Rehermann B, Seef LB, Hoofnagle JH.
Pathogenesis, natural history, treatment and prevention of hepatitis C.
Ann Intern Med.
2000;132:296-305
16.
Thomas DL, Astemborski J, Rai RM, et al.
The natural history of hepatitis C virus infection.
JAMA.
2000;284:450-456
17.
Tong MJ, El-Farra NS, Reikes AR, Co RL.
Clinical outcomes after transfusion-associated hepatitis C.
N Engl J Med.
1995;332:1463-1466 18. Seef LB. The natural history of hepatitis C. Am J Med. 1999;107:10S-15S[Medline] [Order article via Infotrieve]. 19. Niederau C, Lange S, Heintges T. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology. 1998;28:1687-1695[CrossRef][Medline] [Order article via Infotrieve].
20.
Koretz RL, Abbey H, Coleman E, Gitnick G.
Non-A, non-B post-transfusion hepatitis: looking back in the second decade.
Ann Intern Med.
1993;119:110-115 21. Yano M, Kumada H, Kage M. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334-1340[CrossRef][Medline] [Order article via Infotrieve]. 22. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in hemophiliacs. Br J Haematol. 1996;94:746-752[CrossRef][Medline] [Order article via Infotrieve]. 23. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of hemophilic patients. Br J Haematol. 1994;87:555-561[Medline] [Order article via Infotrieve].
24.
Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA.
The natural history of HCV in a cohort of hemophilic patients infected between 1961 and 1985.
Gut.
2000;47:845-851 25. Meijer K, Haagsma EB, Kok T, Schirm J, Smid WM, van der Meer J. Natural history of hepatitis C in HIV-negative patients with congenital coagulation disorders. J Hepatol. 1999;31:400-406[CrossRef][Medline] [Order article via Infotrieve]. 26. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ, for the Multicenter Hemophilia Cohort Study. Natural history of hepatitis C virus infection (HCV) in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr. 1993;6:602-610. 27. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis. 1997;175:164-168[Medline] [Order article via Infotrieve]. 28. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med. 1999;107:79S-84S[CrossRef][Medline] [Order article via Infotrieve].
29.
Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ, for the Multicenter Hemophilia Cohort Study.
Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.
Blood.
1994;84:1020-1023 30. Darby SC, Ewart DW, Giangrande PL, Dolin PJ, Spooner RJ, Rizza CR. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature. 1995;377:79-82[CrossRef][Medline] [Order article via Infotrieve]. 31. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57:775-788[CrossRef][Medline] [Order article via Infotrieve].
32.
Stuyver L, Rossau R, Wyseur A, et al.
Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.
J Gen Virol.
1993;74:1093-1102
33.
Lau JYN, Davis GL, Prescott LE, Maertens G, Lindsay KL, Quan K.
Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States.
Ann Intern Med.
1996;124:868-876 34. Simmonds P, Albert A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C virus genotypes. Hepatology. 1994;19:1321-1324[CrossRef][Medline] [Order article via Infotrieve]. 35. Roffi L, Ricci A, Ogliari C, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol. 1998;29:701-706[CrossRef][Medline] [Order article via Infotrieve].
36.
Santagostino E, Colombo M, Cultraro D, Muca-Perja M, Gringeri A, Mannucci PM.
High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C.
Blood.
1998;92:516-519 37. Tagariello G, Pontisso P, Davoli PG, Ruvoletto MG, Traldi A, Alberti A. Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs. Br J Haematol. 1995;91:708-713[Medline] [Order article via Infotrieve]. 38. Eyster ME, Shermann KE, Goedert JJ, Katsoulidou A, Hatzakis A, for the Multicenter Hemophilia Cohort Study. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. J Infect Dis. 1999;179:1062-1069[CrossRef][Medline] [Order article via Infotrieve]. 39. Telfer PT, Devereux H, Savage K, et al. Chronic hepatitis C virus infection in hemophilic patients: clinical significance of viral genotype. Thromb Haemost. 1995;74:1259-1264[Medline] [Order article via Infotrieve]. 40. Jarvis LM, Ludlam CA, Simmonds P. Hepatitis C virus genotypes in multitransfused individuals. Haemophilia. 1995;1:3-7.
41.
Preston FE, Jarvis LM, Makris M, et al.
Heterogeneity of hepatitis C virus genotypes in hemophilia: relationship with chronic liver disease.
Blood.
1995;85:1259-1262 42. Takayama S, Taki M, Meguro T, Nishikawa K, Shiraki K, Yamada K. Virological characteristics of HCV infection in Japanese haemophiliacs. Haemophilia. 1997;3:131-136.
43.
Jarvis LM, Ludlam CA, Ellender JA, et al.
Investigation of the relative infectivity and pathogenicity of different hepatitis C virus genotypes in hemophiliacs.
Blood.
1996;87:3007-3011 44. Mondelli MU, Silini E. Clinical significance of hepatitis C virus genotypes. J Hepatol. 1999;31(suppl 1):65-70. 45. Hoots K, Canty D. Clotting factor concentrates and immune function in haemophilic patients. Haemophilia. 1998;4:704-713[CrossRef][Medline] [Order article via Infotrieve]. 46. Colombo M, Mannucci PM, Brettler DB, et al. Hepatocellular carcinoma in hemophilia. Am J Hematol. 1991;37:243-246[Medline] [Order article via Infotrieve].
47.
Tradati F, Colombo M, Mannucci PM, et al.
A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C.
Blood.
1998;91:1173-1177 48. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 1997;25:754-758[CrossRef][Medline] [Order article via Infotrieve]. 49. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in hemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet. 1997;350:1425-1431[CrossRef][Medline] [Order article via Infotrieve]. 50. Wong VS, Egner W, Elsey T, Brown D, Alexander GJM. Incidence, character and clinical relevance of mixed cryoglobulinemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol. 1996;104:25-31[CrossRef][Medline] [Order article via Infotrieve]. 51. Akriviadis EA, Xanthakis I, Navrozidou C, Papadopulos A. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha. J Clin Gastroenterol. 1997;25:612-618[CrossRef][Medline] [Order article via Infotrieve]. 52. Lunel F, Musset L. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology. 1994;106:1291-1300[Medline] [Order article via Infotrieve]. 53. Gandini G, Franchini M, Capra F, Aprili G. Clinical relevance of serum cryoglobulins in hemophilic patients with hepatitis C virus infection. Ann Ital Med Int. 1999;14:166-171[Medline] [Order article via Infotrieve]. 54. Lee CA. Investigation of chronic hepatitis C infection in individuals with haemophilia. Br J Haematol. 1997;96:425-426[CrossRef][Medline] [Order article via Infotrieve]. 55. Hanley JP, Jarvis LM, Andrews J, et al. Investigation of chronic hepatitis C infection in individuals with hemophilia: assessment of invasive and non-invasive methods. Br J Haematol. 1996;94:159-165[CrossRef][Medline] [Order article via Infotrieve].
56.
Aledort LM, Levine PH, Hilgartner M, et al.
A study of liver biopsies and liver disease among hemophiliacs.
Blood.
1985;66:367-372 57. Wong VS, Baglin T, Beacham E, Wight DDG, Petrik J, Alexander GJM. The role for liver biopsy in haemophiliacs infected with the hepatitis C virus. Br J Haematol. 1997;97:343-347[CrossRef][Medline] [Order article via Infotrieve]. 58. Telfer P. Liver biopsy for haemophilic patients with chronic HCV infection. Br J Haematol. 1997;99:239-240[Medline] [Order article via Infotrieve]. 59. Venkataramani A, Behling C, Rond R, Glass C, Lyche K. Liver biopsies in adult hemophiliacs with hepatitis C: a United States center's experience. Am J Gastroenterol. 2000;95:2374-2376[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| ||||||||||
 |
|
 |
|
  M. Franchini, C. Mengoli, D. Veneri, R. Mazzi, G. Lippi, and M. Cruciani Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis J. Antimicrob. Chemother., June 1, 2008; 61(6): 1191 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
Top
Abstract
Introduction
-fetoprotein and abdominal ultrasound finding of a focal
lesion. The diagnosis was confirmed bioptically. Only the 2 patients
with HCC underwent liver biopsy. Because no stored sera were available
to define dates of seroconversion for any of the patients, we have
estimated the time and the duration of the HCV infection, assuming that
the first exposure to non-virally inactivated clotting factor
concentrate prepared from pooled donations had transmitted the HCV.
0.5°C).
After hybridization, streptavidin labeled with alkaline phosphatase was
added to trace the hybrid previously formed, and nitroblue tetrazolium
and 5-bromo-4 chloro-3 indoyl-phosphate were used as substrate,
resulting in a colorimetric reaction. Positive line is detected only
when a perfect match between the probe and the biotinylated amplicons occurs. With this standardized assay the 6 major HCV types and their
most common subtypes can be detected simultaneously, and it has been
reported to be highly concordant with other tests for the assignment of
genotype.